Target Name: LOC105375825
NCBI ID: G105375825
Review Report on LOC105375825 Target / Biomarker Content of Review Report on LOC105375825 Target / Biomarker
LOC105375825
Other Name(s): uncharacterized LOC105375825 | Uncharacterized LOC105375825, transcript variant X2 | LOC105375825 variant X2

LOC105375825: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

LOC105375825 is a novel protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function have made it an intriguing target for researchers to study and develop new treatments.

The protein LOC105375825 is a member of the known as the T-cell receptor (TCR) family, which is a critical regulator of immune responses and plays a key role in the development and regulation of many diseases. The TCR family consists of four subfamilies, including ITIM3, ITIM4, NLRP1, and TYRO3. LOC105375825 is a member of the ITIM3 subfamily, which is characterized by the presence of a protein called ITIM4 and a protein called LOC10537581 (LOC105375825).

LOC105375825 is a 21-kDa protein that is expressed in many tissues and cells, including the brain, spinal cord, heart, and peripheral tissues. Its unique function has led to its potential as a drug target and biomarker.

One of the key features of LOC105375825 is its ability to interact with various signaling pathways, including the TCR signaling pathway. The TCR is a critical regulator of immune responses, and LOC105375825 has been shown to play a key role in regulating T cell responses to antigen stimulation.

Research has shown that LOC105375825 is involved in the regulation of T cell clonal expansion, activation, and apoptosis. It has been shown to interact with the protein PD-L1, which is a negative regulator of the TCR signaling pathway. This interaction between LOC105375825 and PD-L1 suggests that it may be a useful target for drugs that are designed to enhance or inhibit T cell responses.

Another potential function of LOC105375825 is its role in neurodegenerative diseases. As we age, the brain is exposed to a variety of toxins and stressors that can lead to the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's. LOC105375825 has been shown to be involved in the regulation of neuroinflammation, which is a key aspect of neurodegenerative diseases.

Research has shown that LOC105375825 is involved in the regulation of the production of pro-inflammatory cytokines, such as TNF-alpha and IL-1-beta, which are involved in the regulation of neuroinflammation. Additionally, LOC105375825 has been shown to interact with the protein TrkB, which is a key regulator of neuroinflammation. This interaction between LOC105375825 and TrkB suggests that it may be a useful target for drugs that are designed to inhibit neuroinflammation.

LOC105375825 has also been shown to be involved in the regulation of immune cell function, which is critical for the regulation of many diseases, including cancer. Research has shown that LOC105375825 is involved in the regulation of the production of immune cells, such as T cells and B cells, which are involved in the regulation of immune responses.

Research has also shown that LOC105375825 is involved in

Protein Name: Uncharacterized LOC105375825

The "LOC105375825 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105375825 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC105375836 | LOC105375855 | LOC105375856 | LOC105375861 | LOC105375875 | LOC105375896 | LOC105375903 | LOC105375911 | LOC105375914 | LOC105375920 | LOC105375922 | LOC105375925 | LOC105375928 | LOC105375931 | LOC105375938 | LOC105375943 | LOC105375951 | LOC105375962 | LOC105375974 | LOC105375976 | LOC105375977 | LOC105375983 | LOC105375984 | LOC105375990 | LOC105375999 | LOC105376001 | LOC105376014 | LOC105376017 | LOC105376035 | LOC105376081 | LOC105376107 | LOC105376110 | LOC105376136 | LOC105376139 | LOC105376156 | LOC105376157 | LOC105376158 | LOC105376161 | LOC105376169 | LOC105376171 | LOC105376177 | LOC105376187 | LOC105376193 | LOC105376196 | LOC105376205 | LOC105376206 | LOC105376208 | LOC105376211 | LOC105376214 | LOC105376219 | LOC105376223 | LOC105376225 | LOC105376234 | LOC105376244 | LOC105376247 | LOC105376250 | LOC105376253 | LOC105376270 | LOC105376287 | LOC105376326 | LOC105376344 | LOC105376356 | LOC105376360 | LOC105376361 | LOC105376372 | LOC105376375 | LOC105376387 | LOC105376391 | LOC105376397 | LOC105376400 | LOC105376407 | LOC105376412 | LOC105376413 | LOC105376422 | LOC105376435 | LOC105376440 | LOC105376442 | LOC105376481 | LOC105376482 | LOC105376483 | LOC105376486 | LOC105376502 | LOC105376504 | LOC105376505 | LOC105376512 | LOC105376523 | LOC105376536 | LOC105376548 | LOC105376558 | LOC105376559 | LOC105376566 | LOC105376576 | LOC105376579 | LOC105376583 | LOC105376595 | LOC105376611 | LOC105376622 | LOC105376626 | LOC105376627 | LOC105376645